Status: current, Sufficiently defined by necessary conditions definition status. Date: 31-Jul 2019. Module: SNOMED CT core module
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3661334010 | Salicylic acid+zinc oxide 5%/20% conventional release cutaneous powder (product) | en | Fully specified name | Inactive | Entire term case insensitive | SNOMED CT core module |
| 3661335011 | Zinc+salicylic acid dusting powder | en | Synonym | Inactive | Entire term case insensitive | SNOMED CT core module |
| 3661336012 | Salicylic acid+zinc oxide 5%/20% conventional release cutaneous powder | en | Synonym | Inactive | Entire term case insensitive | SNOMED CT core module |
| 3763205013 | Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | en | Fully specified name | Active | Entire term case insensitive | SNOMED CT core module |
| 3763206014 | Salicylic acid 50 microgram/mg and zinc oxide 200 microgram/mg cutaneous powder | en | Synonym | Active | Entire term case insensitive | SNOMED CT core module |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Is a | Product containing salicylic acid and zinc oxide | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Has manufactured dose form | Conventional release cutaneous powder | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Is a | Product containing salicylic acid in topical dosage form | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Has active ingredient | Zinc oxide | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Has active ingredient | Salicylic acid | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Is a | Product containing zinc in topical dosage form | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Is a | TEMPORARY parent for CDs that are not updated | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Has concentration strength denominator value | 1 | false | Inferred relationship | Existential restriction modifier | 2 | |
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Has concentration strength numerator unit | microgram | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Has concentration strength denominator unit | milligram | true | Inferred relationship | Existential restriction modifier | 2 | |
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Count of base of active ingredient | 2 | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Has concentration strength denominator value | 1 | false | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Has concentration strength numerator value | 50 | false | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Has concentration strength numerator value | 200 | false | Inferred relationship | Existential restriction modifier | 2 | |
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Has precise active ingredient | Zinc oxide | true | Inferred relationship | Existential restriction modifier | 2 | |
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Has basis of strength substance | Zinc oxide | true | Inferred relationship | Existential restriction modifier | 2 | |
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Has precise active ingredient | Salicylic acid | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Has concentration strength denominator unit | milligram | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Has concentration strength numerator unit | microgram | true | Inferred relationship | Existential restriction modifier | 2 | |
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Has basis of strength substance | Salicylic acid | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Is a | Product containing only salicylic acid and zinc oxide in cutaneous dose form (medicinal product form) | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Plays role | Antifungal therapeutic role | true | Inferred relationship | Existential restriction modifier |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets
FHIR